Drug Application

Foresee Pharmaceuticals signals a major shift to commercialization, appointing Brian J. Groch to lead the launch of its 6-month CPP treatment, FP-001.

Galderma's innovative neuromodulator, a key to its 'powerhouse' ambitions, hits a U.S. roadblock. The FDA's concerns? Manufacturing, not safety.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

A new partnership between Biocartis and City of Hope seeks to transform pancreatic cancer outcomes by pairing breakthrough biomarkers with rapid diagnostic technology.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

A new imaging tool eliminates background noise, offering a revolutionary, high-definition view into the cellular processes that drive life and disease.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.